Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Hematopoietic and Lymphoid Cell Neoplasm: early-phase trial registry
35 of 105 indexed Hematopoietic and Lymphoid Cell Neoplasm trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #125 of 28,707 conditions by registered trial count.
105 US clinical trials · 35 currently recruiting · #125 of 28,707 conditions by registered trial count
Hematopoietic and Lymphoid Cell Neoplasm: 105 US clinical trials tracked, 35 recruiting.
Hematopoietic and Lymphoid Cell Neoplasm is the subject of 105 registered US clinical trials on ClinicalTrials.gov, 35 of them currently open to new participants. 8 are in Phase 3-4 (later-stage) and 44 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 44 of these trials.
Enrollment posture brief
Registry condition hematopoietic-and-lymphoid-cell-neoplasm
OPEN 35 | RECR 33% | LATE 8 | EARLY 44 | RANK #125 | SPON 44
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
Hematopoietic and Lymphoid Cell Neoplasm lists 35 open slots (33% of 105 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Hematopoietic and Lymphoid Cell Neoplasm on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Hematopoietic and Lymphoid Cell Neoplasm is recruiting below its size-band peers.
35 of 105 indexed trials (33.3%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Hematopoietic and Lymphoid Cell Neoplasm research.
M.D. Anderson Cancer Center accounts for 44 of 105 trials (41.9%). 22 distinct sponsors appear on at least one study for this condition label.
-
Typical Hematopoietic and Lymphoid Cell Neoplasm enrolment sits around 72 participants.
Median target enrolment is 72 among the 105 trials that report a genuine target (sentinel values excluded). 57 of those (54.3%) plan for fewer than 100 participants.
-
Hematopoietic and Lymphoid Cell Neoplasm research is mostly interventional.
74 interventional and 31 observational studies make up this index (70.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
105 total, page 1 of 3
Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program
M.D. Anderson Cancer Center
NCT01772771
Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy
M.D. Anderson Cancer Center
NCT00991094
Role of Gut Microbiome in Cancer Therapy
Mayo Clinic
NCT05112614
The Effect of COVID-19 Pandemic on Adolescent and Young Adult Cancer Patients and Survivors
M.D. Anderson Cancer Center
NCT04551378
Collection of Immunology Specimens From Patients With Cancer or Blood Disorders, and Healthy Volunteers
University of Southern California
NCT03207854
Expressive Writing for the Management of Stress in Cancer Survivors
M.D. Anderson Cancer Center
NCT04776941
Comparing Brief Behavioral Therapy (BBT-CI) and Healthy Eating Education Learning (HEAL) for Cancer-Related Sleep Problems While Receiving Cancer Treatment
University of Rochester NCORP Research Base
NCT04829539
Increasing Knowledge and Interest in Cancer Clinical Trials
Hayley Thompson
NCT06501040
Duloxetine and Neurofeedback Training for the Treatment of Chemotherapy Induced Peripheral Neuropathy
M.D. Anderson Cancer Center
NCT04560673
Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients
Alliance for Clinical Trials in Oncology
NCT04939090
Impact of Project ECHO on Improving the Quality of Palliative Care in Patients With Advanced Cancer and Their Caregivers in Underserved Areas of Kenya, Nigeria, Ghana, South Africa, India, and Ethiopia
M.D. Anderson Cancer Center
NCT04984551
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
National Cancer Institute (NCI)
NCT03816345
Non-invasive Ventilation in Reducing the Need for Intubation in Patients With Cancer and Respiratory Failure
M.D. Anderson Cancer Center
NCT02464696
The Longitudinal Impact of Respiratory Viruses on Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Cell Transplantation (The RV-BOS Study)
Fred Hutchinson Cancer Center
NCT05250037
The Impact of COVID-19 on Pulmonary Procedures
M.D. Anderson Cancer Center
NCT05022446
Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy
M.D. Anderson Cancer Center
NCT02710253
Vertebroplasty With Radiation Therapy for Spine Metastatic Cancer Patients With Indeterminate Lesion (SINS Criteria)
Ohio State University Comprehensive Cancer Center
NCT05178472
Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers
AIDS Malignancy Consortium
NCT05663502
Complications and Clinical Response in Cancer Patients Treated With Anti-VEGF-Related Therapies
M.D. Anderson Cancer Center
NCT05108519
Weighted Blanket Use to Reduce Anxiety in Oncology Patients
Ohio State University Comprehensive Cancer Center
NCT06089408
Social Relationships and Accelerated Aging in Hematopoietic Cell Transplant Survivors
Medical College of Wisconsin
NCT04892823
A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients
Children's Oncology Group
NCT05711667
Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies
M.D. Anderson Cancer Center
NCT05011045
Outcomes After Chimeric Antigen Receptor Therapy and Radiation Therapy for Hematologic Malignancies
M.D. Anderson Cancer Center
NCT04888338
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
M.D. Anderson Cancer Center
NCT02962661
Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia
M.D. Anderson Cancer Center
NCT04565665
Exercise Program (TEAM Me) for the Improvement of Movement and Mobility in Pediatric and Adolescent and Young Adult Patients With Cancer Undergoing a Blood Stem Cell Transplant
M.D. Anderson Cancer Center
NCT04678427
Baloxavir and Oseltamivir for the Treatment of Severe Influenza Infection in Immunocompromised Patients
M.D. Anderson Cancer Center
NCT04712539
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
City of Hope Medical Center
NCT04177004
Mobile App to Help Survivors of Childhood Cancer Navigate Long-Term Follow-Up Care
University of California, San Francisco
NCT05641961
Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients
M.D. Anderson Cancer Center
NCT05101213
Alteplase Through an Indwelling Pleural Catheter for the Management of Symptomatic Septated Malignant Pleural Effusion
M.D. Anderson Cancer Center
NCT06184321
Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease
M.D. Anderson Cancer Center
NCT04744116
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
M.D. Anderson Cancer Center
NCT03425526
Formulating Expert Consensus Guidelines in Cancer Care Using the Delphi Method
M.D. Anderson Cancer Center
NCT05054413
Well-Being and Health-Related Quality of Life in Cancer Patients and Survivors During the COVID-19 Pandemic
M.D. Anderson Cancer Center
NCT04500600
An Observational Research Study for Cancer Patients on Immune Checkpoint Inhibitors, DiRECT Study
University of Rochester NCORP Research Base
NCT05364086
Financial Toxicity in Cancer Patients
M.D. Anderson Cancer Center
NCT04592250
Understanding Challenges, Behavioral Patterns, and Preferences Toward Participation in Clinical Trials in Minority Patient Populations: Development of a Personalized Clinical Trial Educational Platform to Increase Participation in Clinical Trials Among Underserved Cancer Patients
Mayo Clinic
NCT04630431
Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors, the StepByStep Study
Children's Oncology Group
NCT04089358
Testing Counseling and Mobile Health Interventions to Improve Physical Activity and Diet Quality in Survivors of Childhood Cancer
Fred Hutchinson Cancer Center
NCT05075759
Cardiovascular Reserve Evaluation in Survivors of Transplant, CREST Study
City of Hope Medical Center
NCT04537871
Financial Navigation Program to Improve Understanding and Management of Financial Aspects of Cancer Care for Patients and Their Spouses
SWOG Cancer Research Network
NCT04960787
Using Technology to Optimize Collaborative Care Management of Depression in Urban and Rural Cancer Centers, SCOPE
University of Washington
NCT05012124
Well-being in Cancer Patients With Neuropathy During COVID-19 Who Participated in Prior Clinical Trials
M.D. Anderson Cancer Center
NCT04650178
Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
M.D. Anderson Cancer Center
NCT02861417
Patient Reported Symptom Control With THC or CBD Use
M.D. Anderson Cancer Center
NCT04875286
Survey Assessment of Patient and Provider Impressions of Telemedicine in Radiation Oncology
M.D. Anderson Cancer Center
NCT05496972
Risk of Chemotherapy Toxicity in Older Patients With Blood Cancer or Non-small Cell Lung Cancer
Ohio State University Comprehensive Cancer Center
NCT05106374
Comprehensive Nutritional Geriatric Assessments in Identifying Malnutrition in Older Cancer Participants
M.D. Anderson Cancer Center
NCT03035604
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 16 |
| Phase 2 | 28 |
| Phase 3 | 5 |
| Phase 4 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Hematopoietic and Lymphoid Cell Neoplasm records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Hematopoietic and Lymphoid Cell Neoplasm trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Hematopoietic and Lymphoid Cell Neoplasm page
105 registered trials, 35 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 35 Hematopoietic and Lymphoid Cell Neoplasm trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Hematopoietic and Lymphoid Cell Neoplasm trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hematopoietic and Lymphoid Cell Neoplasm condition card totals 105 registered trials; most-linked intervention Questionnaire Administration; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.